Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

LifeSci Capital

Tracked across 15 events · 119 articles · First seen Apr 01, 2026 · Last active Sep 21, 2026

Sentiment
15
Attention
4
Events
15
Relationships
2
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 50
Business
Impact: LifeSci Capital served as a joint book-running manager, participating in the offering and benefiting from the transaction.
Jul 31, 2026 · 10 articles
4 55
Business
Impact: LifeSci Capital participated as a joint book-running manager, gaining underwriting fees and exposure in the biotech IPO market. The deal contributes to its deal flow and industry standing.
Aug 07, 2026 · 8 articles
4 10
Business
Impact: LifeSci Capital is acting as a passive book-running manager for the public offering by Altor BioScience.
Jun 03, 2026 · 12 articles
4 10
Business
Impact: LifeSci Capital is acting as a passive book-running manager for the public offering by Enliven Therapeutics.
Jun 11, 2026 · 7 articles
4 0
Business
Impact: LifeSci Capital is acting as a joint bookrunning manager for Neurogene's public offering.
Jun 30, 2026 · 6 articles
2 10
Business
Impact: Acted as joint book-running manager, earning underwriting fees.
Jul 21, 2026 · 6 articles
2 55
Business
Impact: LifeSci Capital acted as passive book-running manager, participating in the offering and earning associated fees.
Aug 05, 2026 · 15 articles
4 5
Business
Impact: LifeSci Capital is acting as a passive bookrunner for the public offering of Spyre Therapeutics' common stock.
Apr 13, 2026 · 7 articles
4 10
Business
Impact: LifeSci Capital is acting as a co-lead manager for the public offering by Celldex Therapeutics.
Apr 01, 2026 · 6 articles
4 5
Business
Impact: LifeSci Capital LLC is acting as a passive bookrunning manager for the initial public offering of Parabilis Medicines.
Jun 10, 2026 · 7 articles
0 0
Business
Impact: LifeSci Capital is hosting the SF Biotech Forum where Immunic will attend.
Jul 09, 2026 · 8 articles
2 5
Business
Impact: LifeSci Capital acted as passive book-running manager for the offering.
Jul 14, 2026 · 7 articles
2 5
Business
Altor BioScience, Inc. (Nasdaq: YARW), a clinical-stage biotechnology company focused on developing therapies for autoimmune thyroid diseases, commenced and then priced an underwritten public offering of 5,769,231 shares of its common stock at $26.00 per…
Impact: LifeSci Capital acted as lead manager for Altor BioScience's public offering, earning underwriting fees.
Sep 10, 2026 · 7 articles
2 5
Business
ADARx Pharmaceuticals, a San Diego-based developer of RNA-based drugs for rare immune, kidney, cardiovascular and neurological diseases, announced on September 21, 2026 that it is seeking a valuation of up to $1.74 billion in its…
Impact: Serving as an underwriter for the ADARx IPO, earning fees from the offering.
Sep 21, 2026 · 6 articles
4 0
Business
Impact: LifeSci Capital acted as a placement agent in connection with the concurrent private placement financing.
Apr 14, 2026 · 7 articles
ERGEN INTELLIGENCE
Track LifeSci Capital live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.